Analysis of Mutations in Pneumocystis jirovecii Dihydropteroate Synthase and Dihydropteroate Reductase Genes Among Non-HIV Patients in China
Yun Wu,Huixin Shi,Wei Li,Yijun An,Yuhan Shao,Xia Rao,Nicholas R Waterfield,Wei Wang,Guowei Yang
DOI: https://doi.org/10.2147/idr.s491478
2024-12-18
Infection and Drug Resistance
Abstract:Yun Wu, 1 Huixin Shi, 1 Wei Li, 1 Yijun An, 1 Yuhan Shao, 1 Xia Rao, 1 Nicholas R Waterfield, 2 Wei Wang, 3 Guowei Yang 1 1 Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China; 2 Warwick Medical School, Warwick University, Coventry, UK; 3 Department of Respiratory Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China Correspondence: Yun Wu; Guowei Yang, Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xi Cheng District, Beijing, 100050, People's Republic of China, Tel +86-10-63139853 ; +86-10-63139130, Email ; Purpose: Pneumocystis jirovecii pneumonia (PJP) shows a high fatality rate in non-HIV patients. However, there are limited data on P. jirovecii drug resistance-related gene mutations in these patients. This study aimed to describe the prevalence of mutations in the dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) genes of P. jirovecii in non-HIV patients in China, providing a reference for drug usage. Methods: We analyzed the polymorphisms of DHPS and DHFR genes from 45 non-HIV patients in China, including P. jirovecii infection (n = 14) and P. jirovecii colonization (n = 31). This analysis also considered clinical characteristics, P. jirovecii burden, treatment response, and prognosis. Results: Compared to the P. jirovecii colonization, P. jirovecii infection had significantly altered blood indicators (GR%, LY%, HGB, TP, ALB, CRP, P < 0.05) with higher P. jirovecii burden ( P < 0.05) and worse prognosis ( P < 0.05). Additionally, patients with P. jirovecii infection were more susceptible to infections, such as the Epstein-Barr virus, Cytomegalovirus, Mycoplasma and Klebsiella pneumoniae. Although no known drug-resistance mutations were detected in the DHPS gene in this study, 10 nonsynonymous mutations were identified. Furthermore, 10 nonsynonymous and 2 synonymous mutations were found in the DHFR gene. However, these mutations were not associated with a worse prognosis. Conclusion: Our results implied that TMP-SMX prophylaxis is still recommended for PJP in high-risk non-HIV patients in China. Keywords: Pneumocystis jirovecii pneumonia, mutation, drug resistance, prognosis, non-HIV Pneumocystis jirovecii pneumonia (PJP) is a severe fungal infection of the lungs caused by Pneumocystis jirovecii . It primarily affects individuals with weakened immune systems, and its mortality rate ranges from 21 to 50%. 1–5 Over the years, preventive measures and advancements in antiretroviral therapy have significantly reduced the infection and mortality rates of PJP in HIV patients. However, the incidence of PJP has been increasing in non-HIV patients with organ transplants, tumors, rheumatic diseases, autoimmune diseases, as well as those using CD20 antibodies and Bruton's tyrosine kinase inhibitors. 6–8 Prophylactic medication is an effective measure in preventing PJP for individuals with weakened immune systems. Currently, the combination of trimethoprim-sulfamethoxazole (TMP-SMX) is considered as the first-line prophylactic treatment for P. jirovecii infections. TMP-SMX targets two folic acid biosynthesis enzymes, dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) of P. jirovecii . While mutations in DHFR have been associated with TMP resistance in various microbial pathogens, their effect on P. jirovecii is less clear. 9,10 Two mutations in DHPS (Thr55Ala and Pro57Ser) are associated with the failure of sulfa prophylaxis and poor treatment outcomes and are therefore considered as TMP-SMX resistance loci. 11–13 P. jirovecii can be transmitted through the air, and individuals with normal immune systems can be asymptomatic carriers, contributing to transmission. 14,15 As patients treated with TMP-SMX might accumulate mutated strains, they could serve as hosts for the transmission of resistance strains. Therefore, environment factors such as this may also contribute to the selection of mutant P. jirovecii strains. 16–18 Thus, by analyzing the drug resistance genes, including DHPS and DHFR, it can effectively guide PJP patient management and treatment decisions. With the increasing number of immunosuppressed patients, P. jirovecii DHPS and DHFR mutations should be taken into account in order to utilize anti- P. jirovecii me -Abstract Truncated-
pharmacology & pharmacy,infectious diseases